Cargando…

Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Young, Jeong, Soung Won, Young Jang, Jae, Jae Kim, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662786/
https://www.ncbi.nlm.nih.gov/pubmed/33142892
http://dx.doi.org/10.3390/ijms21218165
_version_ 1783609477513084928
author Chang, Young
Jeong, Soung Won
Young Jang, Jae
Jae Kim, Yong
author_facet Chang, Young
Jeong, Soung Won
Young Jang, Jae
Jae Kim, Yong
author_sort Chang, Young
collection PubMed
description Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE.
format Online
Article
Text
id pubmed-7662786
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76627862020-11-14 Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma Chang, Young Jeong, Soung Won Young Jang, Jae Jae Kim, Yong Int J Mol Sci Review Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE. MDPI 2020-10-31 /pmc/articles/PMC7662786/ /pubmed/33142892 http://dx.doi.org/10.3390/ijms21218165 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chang, Young
Jeong, Soung Won
Young Jang, Jae
Jae Kim, Yong
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title_full Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title_fullStr Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title_full_unstemmed Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title_short Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
title_sort recent updates of transarterial chemoembolilzation in hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662786/
https://www.ncbi.nlm.nih.gov/pubmed/33142892
http://dx.doi.org/10.3390/ijms21218165
work_keys_str_mv AT changyoung recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma
AT jeongsoungwon recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma
AT youngjangjae recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma
AT jaekimyong recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma